1 | --- | --- | |-------|-------------------------------------------------------------------------------| | | | | | VERVE-101 – an investigational singlecourse gene editing medicine targeting | | | PCSK9 – durably and potently lowers | | | PCSK9 and LDL-C concentrations in | | | non-human primates | | | Amit V. Khera MD, MSc Verve Therapeutics | | | Paul Dudley White International Scholar Awardee | Forward looking statements This press release contains "forward-looking statements" within the meaning of the ...

1 | --- | --- | --- | --- | |-------|-------|------------------------|-------------------------------------------------| | | | | | | | | | | | | | to Treat ASCVD | Verve Therapeutics: In Vivo CRISPR Base Editing | | | | TIDES USA Annual Event | Andrew Bellinger, MD PhD | | | | May 11, 2022 | | Disclosure I am an employee of Verve Therapeutics. This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and ...

1 Verve Therapeutics Disrupting the Care of Cardiovascular Disease through Single-course Gene Editing Medicines January 2022 Forward looking statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding the initiation, and timing, of the Company's planned regulatory submissions, future clinical trials, its research and development plans and the pote ...